IMHO, the game has changed since FDA approval. They have explained the past mistakes (which cost millions) of not having randomized clinical trials and an economic benefit model to sell to the surgeons and hospital admins outside of the US. Also, the fact that there is security from the future BARDA procurement make it less uncertain. If this comes through in FULL, which I don't believe, most likely in stages, it will give management many directions to pursue. So your opinions on the past are some what redundant. This CEO and CCO seem to be the real deal in terms of making it a reality in the US.The next quarterly will be telling.
Ann: Change in substantial holding, page-18
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.84 |
Change
-0.120(3.03%) |
Mkt cap ! $268.3M | |||
| Open | High | Low | Value | Volume |
| $3.94 | $3.94 | $3.76 | $511.0K | 134.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $3.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.84 | 11883 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |